Literature DB >> 28577223

Correspondence between negative symptoms and potential sources of secondary negative symptoms over time.

Aida Farreny1, Mark Savill2,3, Stefan Priebe2.   

Abstract

There has been a debate in the literature about the distinction between primary and secondary negative symptoms of schizophrenia. Our aim was to study the associations between negative symptoms and potential sources of secondary negative symptoms over time. A sample of 275 participants with at least mid-moderate negative symptoms was randomized into body psychotherapy or Pilates class in a previous study. No significant differences were found between groups over time and changes in the symptom domains were modest. The present investigation considers the longitudinal correlation between variables of interest at baseline, 3 and 9 months follow-up. Measures were the Clinical Assessment Interview for Negative Symptoms (CAINS), the Positive and Negative Symptom Scale (PANSS), the Calgary Depression Scale (CDSS) and the Simpson-Angus Extrapyramidal side-effects Scale (SAS). Mixed models were computed to test the longitudinal association between these variables. In a sensitivity analysis, the dosages of antipsychotic, illness duration and allocated intervention were taken into account. Overall, the course of extrapyramidal side-effects, depressive and positive symptoms was significantly related to the course of negative symptoms. Only extrapyramidal effects were longitudinally correlated to expressive negative symptoms. The sensitivity analyses showed unaltered results for positive symptoms and depression but a lack of association between extrapyramidal effects and the CAINS outcomes. In conclusion, the unambiguous interpretation between primary and secondary negative symptoms may lead to refined treatment approaches for schizophrenia and to increased effects of the interventions.

Entities:  

Keywords:  CAINS; Depression; Extrapyramidal effects; Positive symptoms; Primary negative symptoms; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28577223      PMCID: PMC5825294          DOI: 10.1007/s00406-017-0813-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  38 in total

1.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

Review 2.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

3.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

4.  Concepts and methods when considering negative symptom course.

Authors:  W T Carpenter; B Kirkpatrick
Journal:  Psychol Med       Date:  2015-02-25       Impact factor: 7.723

5.  The CAINS: theoretical and practical advances in the assessment of negative symptoms in schizophrenia.

Authors:  Deanna M Barch
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

6.  Treatment of negative symptoms.

Authors:  W T Carpenter; D W Heinrichs; L D Alphs
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

7.  Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.

Authors:  M E Kelley; D P van Kammen; D N Allen
Journal:  Am J Psychiatry       Date:  1999-03       Impact factor: 18.112

8.  Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome.

Authors:  R Tandon; J R DeQuardo; S F Taylor; M McGrath; M Jibson; A Eiser; M Goldman
Journal:  Schizophr Res       Date:  2000-10-27       Impact factor: 4.939

9.  The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

Authors:  Ann M Kring; Raquel E Gur; Jack J Blanchard; William P Horan; Steven P Reise
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

10.  Depressive symptoms in schizophrenic patients.

Authors:  A Gozdzik-Zelazny; L Borecki; M Pokorski
Journal:  Eur J Med Res       Date:  2011-12-02       Impact factor: 2.175

View more
  3 in total

1.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

Review 2.  Splitting Things Apart to Put Them Back Together Again: A Targeted Review and Analysis of Psychological Therapy RCTs Addressing Recovery From Negative Symptoms.

Authors:  Hamish J McLeod
Journal:  Front Psychiatry       Date:  2022-05-12       Impact factor: 5.435

3.  Integration of Clozapine-associated Harm Obsessions into Cognitive Behavioral Conceptualization and Treatment Planning for Thought Broadcasting: A Case Study.

Authors:  Sarah L Kopelovich; Keith Wood; Robert O Cotes; David R Goldsmith
Journal:  J Psychiatr Pract       Date:  2020-07       Impact factor: 1.841

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.